Elicera Therapeutics AB

ELIC

SE0015382080

Pharmaceuticals

Delayed Nasdaq Stockholm Other stock markets 06:29:58 17/06/2024 pm IST			5-day change	1st Jan Change
1.3 ^SEK	-0.38%		-0.76%	-71.49%

11/06	Elicera Therapeutics Enters A Preclinical Collaboration Agreement with China Medical University for the Development of Elc-201	CI
29/05	Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA	CI

Elicera Therapeutics AB Informs Karin Hoogendoorn Decline Re-Election to the Board

January 14, 2022 at 12:42 pm IST

The Nomination Committee of Elicera Therapeutics AB (publ) has thus unanimously proposed a re-election of the current Board. Karin Hoogendoorn has declined re-election.

Latest news about Elicera Therapeutics AB

Elicera Therapeutics Enters A Preclinical Collaboration Agreement with China Medical University for the Development of Elc-201	11/06	CI
Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA	29/05	CI
Elicera Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	27/05	CI
Elicera Therapeutics AB Announces Director Changes	28/03	CI
Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies	06/03	CI
Elicera Therapeutics AB to Present at the Scientific Conference International Society for Cell & Gene Therapy Meeting 2024 in Vancouver, Canada, May 28 to June 1	16/02	CI
Elicera Therapeutics AB Receives Conditional Approval from the Medical Products Agency on Its Car T-Cell Clinical Trial Application to Test ELC-301	14/02	CI
Elicera Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	13/02	CI
Elicera Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/02	CI
Swedish Regulator OKs Elicera’s Clinical Trial for Lymphoma Therapy	09/02	MT
Elicera Therapeutics Receives Approval to Initiate Clinical Phase I/II-Study Carma with Car T-Cell Therapy ELC-301 in B-Cell Lymphoma	09/02	CI
Elicera Therapeutics AB Participates in A Collaborative Project for the Development of Improved Car T-Cell Production That Has Been Awarded Research Support of SEK 850 Thousand	09/01	CI
Elicera Therapeutics AB Co-Founder Receives Grant Totalling 4.8 million SEK from the Swedish Childhood Cancer Fund to Support Car T-Cell Research	22/12	CI
Elicera Therapeutics AB Submits GMP Validation Data to the Swedish Medical Products Agency for the CARMA Study to Supplement the Conditionally Approved Clinical Trial Application	22/12	CI
Elicera Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Elicera Therapeutics AB Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024	31/23/31	CI
Elicera Therapeutics to Receive Chinese Patent for iTANK Platform	08/23/08	MT
Elicera Therapeutics Receives Notice of Allowance for Chinease Patent Protecting the iTANK Platform	08/23/08	CI
Elicera Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/23/29	CI
Elicera Therapeutics AB Announces the Publication of a Scientific Article in the ELC-401 Program	10/23/10	CI
Elicera Therapeutics to Receive European Patent for iTANK Platform	11/23/11	MT
Elicera Therapeutics AB Receives Notice of Allowance for European Patent Protecting the iTANK	11/23/11	CI
Elicera Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Elicera Therapeutics AB Receives Conditional Approval from the Medical Products Agency on its CAR T-Cell Clinical Trial Application to Test ELC-301 (CARMA- Study)	28/23/28	CI
Elicera Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	17/23/17	CI

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The Company is developing next-generation cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.

Sector

Pharmaceuticals

Calendar

16/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELICERA THERAPEUTICS AB	-71.49%	43.47L
ELI LILLY AND COMPANY	+50.70%	79TCr
NOVO NORDISK A/S	+41.51%	63TCr
MERCK & CO., INC.	+18.77%	33TCr
ABBVIE INC.	+8.79%	30TCr
ASTRAZENECA PLC	+17.60%	25TCr
ROCHE HOLDING AG	+0.20%	22TCr
NOVARTIS AG	+9.96%	22TCr
AMGEN INC.	+3.68%	16TCr
PFIZER, INC.	-4.38%	16TCr

Other Pharmaceuticals